Logo Logo
Hilfe
Hilfe
Switch Language to English

San Nicolo, Marion; Hoegerle, Catalina; Gellrich, Donata; Eder, Katharina; Pfrogner, Elisabeth und Groeger, Moritz (2019): The time course of nasal cytokine secretion in patients with aspirin-exacerbated respiratory disease (AERD) undergoing aspirin desensitization: preliminary data. In: European Archives of Oto-Rhino-Laryngology, Bd. 277, Nr. 2: S. 445-452

Volltext auf 'Open Access LMU' nicht verfügbar.

Abstract

Purpose Aspirin-exacerbated respiratory disease (AERD) is a severe form of chronic rhinosinusitis with nasal polyps (CRSwNP) accompanied by asthma and an aspirin intolerance. The underlying pathomechanism of AERD still remains unclear, recent data suggest a complex inflammatory imbalance. In the present study, we investigated the cytokine patterns in AERD, CRSwNP and healthy control patients. Furthermore, we describe the change in cytokine level in the course of aspirin desensitization (AD) with continuous intake of aspirin. Methods The study included a total of 104 participants, 48 healthy controls, 45 patients with nasal polyps and 11 patients with AERD undergoing AD. Nasal secretions were analyzed for IL-1 beta, IL-4, IL-5, IL-10, IL-12, IL-13, IL-17, THF-alpha, IFN-gamma, eotaxin and ECP using Bio-Plex Human Cytokine Assay and Uni-CAP FEIA. Baseline measurements of cytokine levels were performed in all 104 patients;in patients with AERD, follow-up was performed 1-6 and 6-24 months after the initiation of AD. Results Our preliminary results show a T(H)2 dominated, eosinophilic milieu in AERD patients, which decreased in the first weeks of AD. However, after 6 months of AD, proinflammatory cytokines show a tendency to increase again. Also, T(H)1 as well as T-reg associated cytokine seem to increase over time. Conclusions For the first time, the present work shows the cytokine pattern in nasal secretions of AERD patients before and during AD. Further investigation of the complex interaction of inflammatory cytokines during AD might reveal important insights into the disease entity of AERD and open up new horizons for a targeted therapy.

Dokument bearbeiten Dokument bearbeiten